Therapeutic Uses of Dexilant

Dexilant is a medication primarily prescribed to manage conditions characterized by excessive gastric acid production. It belongs to the class of drugs known as proton pump inhibitors (PPIs) and is used to treat various esophageal and gastric issues in adults and children of specific age groups.

Treatment of Erosive Esophagitis

One of the primary uses of Dexilant is the healing of all grades of erosive esophagitis. This condition involves visible inflammation or damage to the lining of the esophagus caused by persistent exposure to stomach acid. The medication helps by reducing acid production, allowing the esophageal tissue to recover and heal over a period of several weeks.

Maintenance of Healed Erosive Esophagitis

Following the successful healing of erosive esophagitis, Dexilant is often used for maintenance therapy. This application is intended to prevent the recurrence of esophageal damage and to provide long-term relief from associated symptoms, such as persistent heartburn.

Management of Gastroesophageal Reflux Disease (GERD)

Dexilant is frequently utilized for the treatment of symptomatic non-erosive gastroesophageal reflux disease (GERD). In these cases, patients experience the discomfort of acid reflux—most notably heartburn—without visible damage to the esophagus. The medication serves to alleviate these symptoms by maintaining a more balanced pH level in the stomach.

Mechanism and Benefits

Dual Delayed Release Technology

The formulation of Dexilant utilizes a specific delivery method designed to release the active ingredient in two distinct phases. This dual delayed-release mechanism is intended to extend the duration of acid suppression throughout the day and night, providing a consistent effect on gastric acidity with a single dose.

Symptom Relief and Quality of Life

By effectively lowering the amount of acid produced in the stomach, Dexilant provides several clinical benefits:

• Reduction of Heartburn: Significant decrease in the frequency and severity of the burning sensation associated with acid reflux.
• Improved Esophageal Health: Protection of the esophageal lining from acid-induced injury.
• Nighttime Symptom Control: Assistance in managing acid-related discomfort that occurs during sleep, which can often disrupt rest.

Who can and cannot use Dexilant?

Official regulatory documents define the specific patient populations eligible for Dexilant.

Absolute Contraindications

The medicine must not be used if there is a known hypersensitivity to any component of the formulation. It is also contraindicated in patients who are concurrently taking rilpivirine-containing products. Individuals diagnosed with rare hereditary problems, such as fructose intolerance or sucrase-isomaltase insufficiency, are likewise ineligible.

Age-Group Eligibility

Dexilant is approved for use in adults and adolescents aged 12 years and older. Safety and efficacy have not been established for children under 12 years of age, and use is not recommended for children less than 2 years.

Conditional Use and Restrictions

• Hepatic Function: Use is not recommended for patients with severe hepatic impairment (Child-Pugh Class C). A maximum daily dose of 30 mg should be considered for patients with moderate hepatic impairment (Child-Pugh Class B).
• Renal Function: No dosage adjustment is necessary for patients with renal impairment.
• Pregnancy and Lactation: Use during pregnancy requires a risk assessment, as animal data indicate potential for adverse effects on fetal bone development. A decision to discontinue the drug or nursing must be made during lactation.

Interactions with Other Medicines and Products

Interactions involving dexlansoprazole, a Proton Pump Inhibitor, are primarily classified based on its effect on gastric acidity and its metabolic clearance.

1. Interactions Due to Altered Gastric pH

The reduction in stomach acid significantly alters the absorption of medicines requiring an acidic environment. Co-administration with the antiretroviral agent rilpivirine is contraindicated by regulatory authorities due to a substantial decrease in rilpivirine plasma concentrations.

Similarly, the absorption of pH-dependent drugs, such as atazanavir, nelfinavir, and certain antifungals like ketoconazole, is reduced, potentially lowering their effectiveness. Conversely, the plasma levels of digoxin may be increased when co-administered.

2. Metabolic and Pharmacodynamic Effects

Dexlansoprazole is metabolized by CYP2C19 and CYP3A4 enzymes. Inhibitors of CYP2C19, such as fluvoxamine, are expected to increase dexlansoprazole exposure, while inducers like rifampicin or the herbal product St John's wort are expected to decrease its exposure.

A pharmacodynamic interaction is documented with warfarin, where co-administration may increase the International Normalized Ratio (INR) and prothrombin time. Furthermore, the administration of dexlansoprazole must be separated by at least one hour from antacids and sucralfate to avoid reduced bioavailability. Systemic exposure is noted to be higher in patients with hepatic impairment.

Dexlansoprazole, the R-enantiomer of lansoprazole, functions as a proton pump inhibitor (PPI). Following absorption, the dual delayed-release formulation results in two distinct plasma concentration peaks, facilitating sustained drug delivery to the gastric parietal cells. In the acidic environment of the secretory canaliculi within these cells, the compound undergoes acid-catalyzed conversion into its active sulphenamide metabolite.

The active metabolite is a non-competitive, irreversible inhibitor. Its biological target is the hydrogen-potassium ATPase (H^+/K^+-ATPase), also known as the proton pump, which is embedded in the apical membrane of the parietal cell. The sulphenamide metabolite forms a covalent disulfide bond with specific cysteine residues on the extracellular domain of the proton pump, thereby inactivating the enzyme. This direct interaction blocks the final step of gastric acid secretion, which is the exchange of intracellular hydrogen ions (H^+) for extracellular potassium ions (K^+).

The downstream cascade results in a sustained, non-reversible reduction in the transport of hydrochloric acid into the gastric lumen. This system-level physiological consequence is a decrease in both basal and stimulated gastric acid output, leading to an increase in intragastric pH.

The medication is approved for oral administration as a Dual Delayed Release (DDR) capsule and is to be taken once daily. The DDR formulation allows the capsule to be administered without regard to food at any time of day. The standard use pattern is officially defined by the specific goal of treatment, which dictates the required dose and course duration.

Indication	Standard Adult Dose	Duration of Use
Healing of Erosive Esophagitis (EE)	60 mg once daily	Up to 8 weeks
Maintenance of Healed EE	30 mg once daily	Up to 6 months
Symptomatic Non-Erosive GERD	30 mg once daily	4 weeks

The capsule must be swallowed whole to maintain the integrity of the two-stage release mechanism. If swallowing the capsule is not possible, the granules may be administered immediately after mixing with one tablespoon of applesauce or water, but the granules must not be chewed, and the mixture must not be saved for later use. Administration is approved for patients 12 years of age and older.

For special populations, the official label specifies that no dosage adjustment is required for patients with renal impairment or for older adults. However, the maximum daily dose for patients with moderate hepatic impairment (Child-Pugh Class B) is limited to 30 mg for a period up to 8 weeks. If a dose is missed, it should be taken as soon as possible, but two doses must never be taken simultaneously to compensate.

Research Evidence / Overview of Studies for Дексилант

---

Studies related to Healing and Maintenance of Esophagus Damage (Erosive Esophagitis)

This section outlines the scientific studies that have been conducted to understand the effects of Дексилант in people with erosive esophagitis, a condition linked to acid reflux where there are sores or damage in the lining of the esophagus. The research has primarily explored the outcomes related to physical discomfort and patterns observed in studies related to the healing of the lining.

Studies examined the patterns observed in studies regarding the healing of erosions in the esophagus lining over a short, defined time interval. Further research explored patterns observed in studies regarding the maintenance of healed states over time. These findings contribute to understanding symptom patterns and outcomes reflecting daily functioning in this specific patient group.

While the research provides insight into short-term changes, the results apply only to the populations studied. We will review information from studies, including those using a non-treatment (placebo) approach.

Studies related to Outcomes for Heartburn in Non-Erosive Reflux Disease (GERD)

Research has evaluated Дексилант in people with non-erosive reflux disease (NERD), which is a condition characterized by fluctuating or episodic manifestations like heartburn, where no visible damage is present in the esophagus. The primary focus of these studies was observed in outcomes related to physical discomfort, specifically how often and how severely heartburn symptoms were experienced.

Studies focusing on episodes where symptoms become more noticeable have monitored patient-reported outcomes describing perceived discomfort. The data show patterns related to outcomes related to physical discomfort during the study period compared to a non-treatment (placebo) period. The evidence so far describes patterns related to outcomes related to physical discomfort, but how individual patients will respond does not determine whether an individual will respond similarly.

---

Long-term Studies and Follow-up

Research examined the patterns observed when this medicine was used over extended time intervals beyond the initial treatment phase. The research describes patient-reported outcomes related to systemic or functional imbalance over defined time intervals. Long-term effects are not fully established, and evidence describing patterns observed over many years is limited.

Evidence in Special Populations

Research has examined the use of Дексилант in certain special groups, including children and adolescents (ages 12–17) for the main conditions studied. Data for other special groups remain insufficient, and evidence quality varies across studies for these populations.

What is Still Uncertain About Дексилант

The findings in some research scenarios were mixed, and certainty remains low regarding the full range of outcomes related to physical discomfort across all conditions and patient types. Research is ongoing to further clarify questions around the approach for conditions marked by functional limitations. The evidence highlights what is known—and what is still uncertain—about this medicine.

Common questions about Дексилант (FAQ)

Q: What is the main use of Дексилант?

A: The medicine is officially approved for the management of conditions related to excess stomach acid. This includes healing damage in the esophagus, known as erosive esophagitis, maintaining that healing once achieved, and treating the symptom of heartburn in non-erosive reflux disease (GERD).

Q: How is Дексилант different from other common acid reducers?

A: The key difference is its unique formulation. It is an R-enantiomer of lansoprazole and is manufactured as a Dual Delayed Release (DDR) capsule. This design allows the drug to be released into the body in two separate stages hours apart.

Q: Does Дексилант come in different strengths?

A: Yes, the medicine is officially available in two capsule strengths. According to official product information, these delayed-release capsules are available in two formulations corresponding to the 30 mg and 60 mg dosage levels.

Q: Can Дексилант be used for long periods?

A: According to official guidance, the medicine is approved for maintenance therapy for up to six months. However, regulatory documents indicate that using proton pump inhibitors for a year or longer is associated with increased risks, such as bone fractures.

Q: Is Дексилант known to interact with commonly used over-the-counter pain relievers?

A: The official drug information does not specifically name common OTC pain relievers like ibuprofen or acetaminophen. However, the medicine works by reducing stomach acid, which can affect how the body absorbs other drugs. It is important to consider that the absorption of any medicine requiring an acidic environment may be altered.

Q: Is it possible for Дексилант to cause dizziness?

A: Dizziness is not listed among the most commonly reported side effects in clinical trials (those reported in 2% or more of patients). However, the official prescribing information notes that dizziness has been reported in postmarketing experience or in less common categories for this drug class.

Q: How quickly is Дексилант expected to start working?

A: The Dual Delayed Release design means the active ingredient is released in two phases for sustained acid control. Some medication is released quickly, about one hour after taking it, and the rest is released later, approximately four to five hours after the first release.

Q: Is Дексилант the same as Prevacid?

A: No, they are not the same medicine but they are chemically related. Dexlansoprazole is officially classified as the R-enantiomer of lansoprazole, which is the active ingredient in Prevacid.

Q: What are the signs of a serious, but rare, allergic reaction to Дексилант?

A: Serious allergic reactions, known as hypersensitivity reactions, are infrequent but have been reported. These can include severe skin reactions, such as Stevens-Johnson syndrome, or life-threatening reactions like anaphylaxis. If signs of a serious reaction are observed, urgent consultation with a healthcare professional is advised, as noted in official documents.

Q: Is there evidence about using Дексилант for conditions other than acid reflux?

A: Official prescribing information indicates that the medicine is only approved for conditions directly related to acid reflux. These approved uses are specifically for erosive esophagitis and symptomatic gastroesophageal reflux disease (GERD).

Q: Why is the active ingredient in Дексилант called 'dexlansoprazole'?

A: The name is based on the drug's chemical structure. It is officially described as the R-enantiomer, often indicated by the prefix 'dex', of the related proton pump inhibitor, lansoprazole.

Q: What does official guidance say about stopping Дексилант?

A: Official guidance indicates that the drug’s discontinuation is required if certain serious adverse reactions develop. These include acute tubulointerstitial nephritis (a type of kidney inflammation) or severe skin or immune-related reactions.

Q: Is it normal to feel a change in appetite while using Дексилант?

A: A decrease in appetite, medically known as anorexia, is not listed as a common side effect in clinical trials. However, official postmarketing reports indicate that this has been observed in some people using this class of medicine.

Q: Are there any high-level summaries of clinical trials for Дексилант?

A: Yes, the official clinical study information provides summaries of trials for the approved uses. The findings describe the patterns related to use for healing and maintenance of erosive esophagitis, as well as for treating heartburn associated with symptomatic GERD.

Q: Is there a known interaction between Дексилант and iron supplements?

A: Yes, a possible interaction is documented. The medicine reduces stomach acid. The change in stomach acidity may alter the absorption of certain nutrients and drugs, including iron salts, whose effectiveness may be affected.

Q: Are there any known issues with taking Дексилант with certain antibiotics?

A: The official drug information notes that taking the medicine may lead to lower levels or reduced effect of certain antibiotics, such as ampicillin, due to the change in gastric pH.

Q: What are the main findings from research on Дексилант for healing erosive esophagitis?

A: Clinical studies evaluating the healing of erosive esophagitis compared the 60 mg dose of dexlansoprazole to a standard dose of racemic lansoprazole. The research indicated that the 60 mg dose showed similar patterns of healing compared to the reference drug used in the study.

Q: Why might a doctor prescribe Дексилант instead of an older PPI?

A: The main distinguishing feature noted in official documents is its Dual Delayed Release formulation. This unique design is engineered to provide two distinct releases, which results in prolonged exposure intended to maintain acid control throughout the day.

Q: Does regulatory guidance mention any mood-related side effects for Дексилант?

A: No mood-related effects like depression or anxiety are listed among the common side effects. However, long-term use carries a risk of Vitamin B12 deficiency. Some symptoms associated with severe B12 deficiency may involve neurological changes, such as confusion.

Q: What is the main risk noted for patients with a history of Clostridium difficile-associated diarrhea when using Дексилант?

A: Regulatory warnings indicate that using a proton pump inhibitor, including this medicine, may be associated with an increased risk of developing Clostridium difficile-associated diarrhea (CDAD). This risk is a general caution for the PPI drug class.

Dexilant delayed-release capsules must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be stored in a closed container and protected from excessive heat, moisture, and direct light, and it should be kept out of the reach of children.

Stability and Disposal

Classification	Requirement
Stability after mixing	Granules mixed with applesauce or water must be swallowed immediately; the mixture must not be saved for later use.
Disposal	The medicine must be disposed of via a drug take-back program. If this is unavailable, it must be mixed with an undesirable substance (e.g., used coffee grounds, dirt), sealed in a container, and thrown into the household trash.
Protection	The product is not on the list of medicines recommended for flushing down the toilet. All personal information on the prescription label must be scratched out before disposal.